Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Wright-Patterson Medical Center
mi
from
Wright-Patterson Air Force Base, OH
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Wright-Patterson Medical Center
mi
from
Wright-Patterson Air Force Base, OH
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Legacy Mount Hood Medical Center
mi
from
Gresham, OR
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Legacy Mount Hood Medical Center
mi
from
Gresham, OR
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Orange
mi
from
Orange, CA
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Orange
mi
from
Orange, CA
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Penrose Cancer Center
mi
from
Colorado Springs, CO
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Penrose Cancer Center
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health Services, Inc
mi
from
Newark, DE
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health Services, Inc
mi
from
Newark, DE
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Northside Hospital
mi
from
Atlanta, GA
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
St. Joseph's/Candler Health System
mi
from
Savannah, GA
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
St. Joseph's/Candler Health System
mi
from
Savannah, GA
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Our Lady of the Lake/ Mary Bird Perkins
mi
from
Baton Rouge, LA
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Our Lady of the Lake/ Mary Bird Perkins
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
The Cancer Institute Catholic Health Initiatives
mi
from
Towson, MD
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
The Cancer Institute Catholic Health Initiatives
mi
from
Towson, MD
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Billings Clinical Cancer Center
mi
from
Billings, MT
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Billings Clinical Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
CHI, St. Fancis
mi
from
Grand Island, NE
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
CHI, St. Fancis
mi
from
Grand Island, NE
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
CHI, Good Samaritan
mi
from
Kearney, NE
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
CHI, Good Samaritan
mi
from
Kearney, NE
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Hospital
mi
from
Allentown, PA
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Hospital
mi
from
Allentown, PA
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Spartanburg Regional Hospital
mi
from
Spartanburg, SC
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Spartanburg Regional Hospital
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Sanford Health
mi
from
Sioux Falls, SD
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Sanford Health
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Ascension Health Systems
mi
from
Milwaukee, WI
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Ascension Health Systems
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
DFCI at Faulkner Hospital
mi
from
Boston, MA
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
DFCI at Faulkner Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
New Hampshire Oncology-Hematology, PA
mi
from
Concord, NH
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
New Hampshire Oncology-Hematology, PA
mi
from
Concord, NH
Click here to add this to my saved trials
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Univ of North Carolina
mi
from
Chapel Hill, NC
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Samuel Oschin Comprehensive Cancer Institute - Cedars Sinai Medical Center
mi
from
Beverly Hills, CA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Samuel Oschin Comprehensive Cancer Institute - Cedars Sinai Medical Center
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Sarcoma Oncology Research Center
mi
from
Santa Monica, CA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Sarcoma Oncology Research Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
St. Joseph Heritage Healthcare
mi
from
Santa Rosa, CA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
St. Joseph Heritage Healthcare
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Memorial Hospital of South Bend
mi
from
South Bend, IN
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Memorial Hospital of South Bend
mi
from
South Bend, IN
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas
mi
from
Wichita, KA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Medstar Health - Union Memorial Hospital
mi
from
Baltimore, MD
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Medstar Health - Union Memorial Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Medstar Health - Weinberg Cancer Institute at Franklin Square
mi
from
Baltimore, MD
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Medstar Health - Weinberg Cancer Institute at Franklin Square
mi
from
Baltimore, MD
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
MedStar Health - Good Samaritan Hospital
mi
from
Baltimore, MD
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
MedStar Health - Good Samaritan Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Tisch Cancer Institute/Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Tisch Cancer Institute/Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Legacy Health, Legacy Good Samaritan Medical Center
mi
from
Portland, OR
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Legacy Health, Legacy Good Samaritan Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University [Kimmel Cancer Center]
mi
from
Philadelphia, PA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University [Kimmel Cancer Center]
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Providence Regional Medical Center
mi
from
Everett, WA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Providence Regional Medical Center
mi
from
Everett, WA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Swedish Cancer Institute
mi
from
Seattle, WA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Columbia - St. Mary's
mi
from
Milwaukee, WI
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Columbia - St. Mary's
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Deerfield Beach, FL
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Deerfield Beach, FL
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Kendall, FL
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Kendall, FL
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Plantation, FL
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Plantation, FL
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Valley Hospital
mi
from
Paramus, NJ
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Valley Hospital
mi
from
Paramus, NJ
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Texas Oncology (Cancer Care Centers of South Texas)
mi
from
San Antonio, TX
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Texas Oncology (Cancer Care Centers of South Texas)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Franciscan Health Indianapolis
mi
from
Indianapolis, IN
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Franciscan Health Indianapolis
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Sibley Memorial Hospital
mi
from
Washington,
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Sibley Memorial Hospital
mi
from
Washington,
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Katzen Cancer Research Center, George Washington University
mi
from
Washington,
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Katzen Cancer Research Center, George Washington University
mi
from
Washington,
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
North Shore Hematology Oncology Associates
mi
from
Bronx, NY
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
North Shore Hematology Oncology Associates
mi
from
Bronx, NY
Click here to add this to my saved trials